Radar · Life Sciences in Jiangsu
Best Life Sciences Companies in Jiangsu, China
The 191 best Life Sciences companies in Jiangsu, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Abogen Biosciences.
By Rohit KhannaTrends & Stories
191companies tracked
$6Bdisclosed funding
2unicorns
105have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × JIANGSU
Our analysis of 50 Life Sciences companies
$5.7b in tracked funding; 40% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
40%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2017median founding year
247kcombined LinkedIn audience
87%of audience held by top 3
3companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Jiangsu
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Abogen Biosciences 🦄 Developer of mRNA-based therapeutics for cancer and infectious diseases 55Moat top 14%Patents top 17%Innovation top 22%Funding top 27% All 8 signals ▾Moattop 14% Patentstop 17% Innovationtop 22% Fundingtop 27% Talenttop 38% Marketbottom 44% Globalbottom 43% Techbottom 24% Moat: Editorial + unicorn rating 9/10 · IP moat: 157 patents Patents: 157 patents matched (strict assignee match) · 154 filings since 2022 vs 3 in 2017-21 rank vs industry peers · Fliar Intelligence Index 55/100 | $1.1B | 49 mo ago | Series C | — | Dr InBev Co-Founder & Co-CEO | 157 patents mRNA and circular RNA therapeutics with lipid nanoparticle delivery systems | — |
| 2 | Innovent Bio Developer of antibody therapeutics for multiple diseases | $535M | 46 mo ago | Public | 5,144 | Michael Yu Founder & CEO | — | 1 partnership |
| 3 | Genecast Non-invasive diagnosis and monitoring of cancer | $246M | 67 mo ago | Series E | — | Ma Guosheng Co-Founder & VP | — | 1 job opening · 1 partnership |
| 4 | CF PharmTech Chinese, commercial-stage, specialty Respiratory-focused drug-delivery development company and CDMO | $206M | 71 mo ago | Public | 550 | — | 40 patents Advanced aerosol drug delivery systems and formulation technologies for inhalable therapeutics. | — |
| 5 | Transcenta Developer of antibody-based therapeutics | $205M | 65 mo ago | Public | 318 | Xueming Qian Co-Founder & CEO | — | — |
| 6 | Souzhou Ribo Life Science Developer of nucleic acid drugs based on RNA interference (RNAi) technology | $201M | 46 mo ago | Public | 228 | Zicai Liang Founder | — | — |
| 7 | Frontera Therapeutics Developer of AAV-based gene therapies for the treatment of rare and chronic diseases | $195M | 47 mo ago | Series B | 41 | — | — | — |
| 8 | Suzhou Connect Biopharmaceuticals Discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation | $195M | 69 mo ago | Public | 100 | Zheng Wei Co-Founder & CEO | 87 patents Therapeutic antibodies targeting IL‑4Rα and novel S1P1 receptor agonist salts | — |
| 9 | IASO BIO Provider of pharmaceuticals for cell therapies for oncology | $178M | 41 mo ago | Series C | 400 | Jinhua Zhang Co-Founder & CEO | — | — |
| 10 | Alphamab Oncology 🦄 Developer of antibodies for the treatment of cancer diseases | $160M | 84 mo ago | Public | 31 | — | — | — |
| 11 | Adagene Developer of immunotherapy for the treatment of cancer 37Funding top 18%Product top 24%Moat top 38%Tech top 42% All 12 signals ▾Fundingtop 18% Producttop 24% Moattop 38% Techtop 42% Globaltop 43% Partnerstop 45% Patentstop 46% Talentbottom 49% Growthbottom 42% Innovationbottom 38% Marketbottom 36% Newsbottom 23% Funding: Raised $157M across 5 rounds · 5 rounds over 12 yrs (0.4/yr) Product: 2 distinct product lines · Company stage: Public rank vs industry peers · Fliar Intelligence Index 37/100 | $157M | 11 mo ago | Public | 15 | Peter Luo Founder & CEO | 26 patents Antibody library engineering and heterodimeric Fc protein therapeutics for cancer treatment | — |
| 12 | New Element Medicine Developer of drugs for various cancer | $152M | 32 mo ago | Series D | — | Shi Dongfang Founder & CEO | — | — |
| 13 | Legend Biotechnology Developer of cell therapy to treat cancer and infectious diseases | $150M | 38 mo ago | Public | 1,576 | Yuan Xu CEO | — | — |
| 14 | Impact Therapeutics Developer of small molecule therapeutics for the treatment of cancer 50Patents top 18%Funding top 21%Innovation top 23%Moat top 26% All 6 signals ▾Patentstop 18% Fundingtop 21% Innovationtop 23% Moattop 26% Globalbottom 43% Marketbottom 26% Patents: 226 patents matched (strict assignee match) · 118 filings since 2022 vs 76 in 2017-21 Funding: Raised $145M across 5 rounds · 5 rounds over 12 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $145M | 19 mo ago | Public | 7 | — | 226 patents Small-molecule inhibitors of PARP, kinases, and DHX9 for cancer therapy | — |
| 15 | Sinovent Developer of small molecule drugs for the treatment of tumour, CNS, autoimmunity, and infectious disease | $145M | 65 mo ago | Deadpooled | 50 | Jing Qiang Founder | — | — |
| 16 | Doma Pharmaceutical Technology Developer of drugs for the treatment of cancer | $142M | 48 mo ago | Series A | — | Shen Yuelei Chairman | — | — |
| 17 | Virtue Diagnostics Provider of an in vitro assay platform for diagnostic solutions | $130M | 53 mo ago | Series B | 500 | Johnson Zhang CEO | — | 1 job opening |
| 18 | MediLink Developer of antibody-drug conjugates for cancer treatment | $120M | 51 mo ago | Series B | 49 49 → 60 (+22%) | Jiaqiang Cai Co-Founder & CSO | — | — |
| 19 | Peijia Medical Technologies Developer of medical devices for the treatment of cardiac and cerebrovascular diseases | $110M | 79 mo ago | Public | 1,006 | — | — | — |
| 20 | Tot Biopharm Chinese oncology drug development and manufacturing company | $108M | 94 mo ago | Series B | — | — | — | — |
| 21 | Triastek Provider of 3D printing pharmaceutical technology platform for drug design 69Innovation top 15%Patents top 18%Funding top 31%Moat top 37% All 8 signals ▾Innovationtop 15% Patentstop 18% Fundingtop 31% Moattop 37% Talenttop 38% Marketbottom 45% Globalbottom 40% Newsbottom 22% Innovation: 196 patents (top 7% of patent-holders) · 125 filings since 2022 vs 68 in 2017-21 Patents: 196 patents matched (strict assignee match) · 125 filings since 2022 vs 68 in 2017-21 rank vs industry peers · Fliar Intelligence Index 69/100 | $102M | 32 mo ago | Series B | 46 | Xiaoling Li Co-Founder | 196 patents Advanced pharmaceutical dosage forms and additive manufacturing for controlled-release capsules | — |
| 22 | Xinrong Medical Portfolio of trauma and fixation systems | $100M | 140 mo ago | Late Stage | 4 | — | — | — |
| 23 | Evopoint Developer of therapeutics for multiple diseases | $97M | 27 mo ago | Series E | — | Nianfeng Ju Co-Founder | — | — |
| 24 | Eluminex Biosciences Developer of therapeutics for ocular disorders | $90M | 39 mo ago | Series B | 65 | JZ Zhang Founder & CEO | 27 patents Multispecific antibody‑fusion biologics targeting IL‑6/angiogenesis and ocular retinoid therapies | — |
| 25 | GemPharmatech Provider of humanized models and drug screening technologies | $82M | 69 mo ago | Public | 10 | — | 24 patents Genetically engineered mouse models for disease study and humanized antibody production | — |
| 26 | CureGenetics Provider of CRISPR-Cas9 based gene-editing technology for therapy and diagnosis | $79M | 53 mo ago | Series B | 17 | Yanni Lin Co-founder and Chief Scientist | — | — |
| 27 | Biosion Developer of antibody-based therapeutics to treat various diseases | $76M | 37 mo ago | Series B | 90 | Mingjiu Chen Founder & Chairman &CEO | 131 patents Therapeutic antibodies and fusion proteins for immune checkpoint and tumor antigen targeting | 1 launch |
| 28 | CMAB Biopharma Developer and manufacturer of biologic products | $72M | 98 mo ago | Acqui-Hired | 250 | — | — | — |
| 29 | SceneRay Developer of a portfolio of Neuromodulation devices | $63M | 52 mo ago | Series D | 29 | — | 158 patents Neuromodulation devices and surgical planning systems for targeted nerve stimulation | 1 partnership |
| 30 | Accropeutics Developer of drugs for inflammation, autoimmune diseases, and cancer 57Funding top 20%Talent top 38%Market bottom 49%Global bottom 48% All 4 signals ▾Fundingtop 20% Talenttop 38% Marketbottom 49% Globalbottom 48% Funding: Raised $62.0M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 57/100 | $62M | 1 mo ago | Series C | — | Xiaohu Zhang Co-Founder & CEO | — | — |
| 31 | Beikang Medical Developer of NGS-based diagnostic solutions for neonatal | $37M | 73 mo ago | Public | 488 | — | — | — |
| 32 | Qinhao Pharmaceutical Developer of small-molecule therapeutics for tumor and fibrosis | $31M | 52 mo ago | Series B | 14 | Kuifeng Wang Founder & CEO | — | — |
| 33 | Sniper Developer of droplet digital PCR | $31M | 56 mo ago | Series B | — | Sheng Guangji Founder | — | — |
| 34 | Nanjing Wei Li Zhi Bo Biotechnology Provides research and development for tumour immunotherapy | $30M | 67 mo ago | Public | — | Xiaoqiang Kang Chairman & CEO | — | — |
| 35 | 4B Technologies Developer of drugs for neurological disorders | $25M | 42 mo ago | Series A | 9 | Liu Jie Co-Founder | — | — |
| 36 | Zhangjiagang Wanzhongyixin Biological Technology Developer of bio-detection chips and electronic biochemical sensors | $24M | 32 mo ago | Series B | 80 | — | — | — |
| 37 | Starna Therapeutics Developer of RNA-based drugs for multiple diseases 29Funding top 34%Moat top 38%Talent bottom 49%Market bottom 37% All 5 signals ▾Fundingtop 34% Moattop 38% Talentbottom 49% Marketbottom 37% Globalbottom 36% Funding: Raised $22.1M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 29/100 | $22M | 7 mo ago | Series B | — | Rongkuan Hu Founder | — | — |
| 38 | Novlead Developer of medical devices for pulmonary diseases | $19M | 55 mo ago | Series B | 111 | — | — | — |
| 39 | Ractigen Provider of siRNA therapeutics to silence transcription repressors for the treatment of oncology, dermatology… | $17M | 52 mo ago | Series A | — | Long-Cheng Li Co-founder | — | 1 job opening |
| 40 | Nanjing Nuoyuan Medical Developer of medical imaging diagnostic devices | $16M | 52 mo ago | Series B | — | Huiming Cai Founder & CEO | 54 patents Near‑infrared fluorescent probes for tumor imaging and surgical navigation | — |
| 41 | Kossel Medtech Developer of cardiovascular medical devices | $16M | 29 mo ago | Series B | — | Navis Feng Co-Founder | 6 patents Patents concentrated in health & consumer products | — |
| 42 | Changzhou Sail Medical Technology Manufacturer of dental equipment and CBCT systems. The company produces a wide array of products for… | $16M | 41 mo ago | Series B | 300 | — | — | — |
| 43 | Hongyun Biotech Provider of therapeutics solution for the treatment of cancer and other rare diseases | $16M | 37 mo ago | Series B | — | Xin Huang CEO | — | — |
| 44 | Pulnovo Medical Developer of a medical device for the treatment of pulmonary hypertension 62Moat top 25%Patents top 31%Innovation top 33%Funding top 38% All 9 signals ▾Moattop 25% Patentstop 31% Innovationtop 33% Fundingtop 38% Markettop 39% Growthtop 48% Talentbottom 49% Globalbottom 43% Newsbottom 34% Moat: Editorial + unicorn rating 7/10 · IP moat: 38 patents Patents: 38 patents matched (strict assignee match) · 27 filings since 2022 vs 10 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $15M | 15 mo ago | Series C | 100 | Jessie Lian CEO | 38 patents Catheter-based radiofrequency ablation of the pulmonary artery for heart‑failure therapy | 1 partnership |
| 45 | magAssist Developer of extracorporeal circulation assisting device | $15M | 56 mo ago | Series C | — | Polin Hsu Founder | 100 patents Design and integration of catheter pump systems for ventricular assist and fluid management | 1 award |
| 46 | Healrna Developer of nucleic acid drugs to treat various diseases | $15M | 39 mo ago | Seed | — | Zhong Tianyi Co-Founder & CEO | — | — |
| 47 | Iongen Therepeutics Developer of novel analgesic drugs targeting Nav1.8 and Nav1.7 ion channels 60Funding top 42%Talent top 45%Global bottom 48% All 3 signals ▾Fundingtop 42% Talenttop 45% Globalbottom 48% Funding: Raised $13.6M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 2 named leaders on record rank vs industry peers · Fliar Intelligence Index 60/100 | $14M | 17 mo ago | Seed | — | Yang Yong Co-Founder | — | — |
| 48 | Convergen Pharmaceuticals Provider of a platform utilizing Generative AI to accelerate drug discovery and development for the biotech… 48Funding top 41%AI top 45%Talent bottom 45%Global bottom 33% All 4 signals ▾Fundingtop 41% AItop 45% Talentbottom 45% Globalbottom 33% Funding: Raised $10.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) AI: Product described with: generative ai rank vs industry peers · Fliar Intelligence Index 48/100 | $10M | 6 mo ago | Seed | — | Jinquan Sun Co-Founder & CEO | — | — |
| 49 | Big Vision Provider of ophthalmology diagnosis and analysis systems | $9M | 25 mo ago | Series A | — | Chen Xinjian Founder | — | — |
| 50 | Beta Pharmaceutical Technology Developer of disease diagnostic reagents 55Innovation top 32%Moat top 32%Patents top 33%Talent bottom 45% All 6 signals ▾Innovationtop 32% Moattop 32% Patentstop 33% Talentbottom 45% Fundingbottom 43% Globalbottom 29% Innovation: 49 patents (top 48% of patent-holders) · 42 filings since 2022 vs 7 in 2017-21 Moat: Editorial + unicorn rating 4/10 · IP moat: 49 patents rank vs industry peers · Fliar Intelligence Index 55/100 | $1M | 7 mo ago | Series C | — | Zhu Chenggu CEO | 49 patents Antiviral and protein‑misfolding therapeutics using PI4K inhibitors and arsenic‑based compounds | — |
Top 12 Life Sciences companies in Jiangsu
#1
Series C · Suzhou, Jiangsu · founded 2017$62Mraised▾
Series C · Suzhou, Jiangsu · founded 2017
Developer of drugs for inflammation, autoimmune diseases, and cancer. The pipeline includes AC-003 Receptor -interacting protein kinase1 for Idiopathic pulmonary fibrosis, Graft versus Host Disease, AC-101 for inflammatory bowel disease, AC-201, an allosteric TYK2/JAK1 inhibitor for psoriasis, and others.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 20%Talent
top 38%Market
bottom 49%Global
bottom 48%Funding: Raised $62.0M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) · Last round Series C (May 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 131 LinkedIn followers
Funding rounds
- May 2026Series C$50M
- Mar 2025Series B$12M
Founders & team
Investors
Shenzhen Capital Group, Morningside, Suzhou Industrial Park Leading Venture Capital, Hefei Sci-Tec, Orbimed, TCG Crossover
#2
Public · Suzhou, Jiangsu · founded 2012 · 15 employees$157.4Mraised▾
Public · Suzhou, Jiangsu · founded 2012 · 15 employees
Developer of immunotherapy for the treatment of cancer. It is developing antibodies which include ADG106 which is an agonist for CD137 in metastatic solid tumors, ADG126 targets CTLA4 for cancer therapy, and aADG116 targets epitope of CTLA4 in metastatic solid tumors and relapsed/refractory non-Hodgkin’s lymphoma.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 18%Product
top 24%Moat
top 38%Tech
top 42%Global
top 43%Partners
top 45%Funding: Raised $157M across 5 rounds · 5 rounds over 12 yrs (0.4/yr) · Last round Post IPO (Jul 2025)
Product: 2 distinct product lines · Company stage: Public
Moat: Editorial + unicorn rating 5/10 · IP moat: 26 patents · 10 curated direct competitors tracked
Audience (LinkedIn): 5k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. Incyte) announced in 12 mo
Funding rounds
- Jul 2025Post IPO$25M
- Jan 2020Series D$69M
- Mar 2018Series C$50M
- Jan 2016Series B$28M
Founders & team
Investors
General Atlantic, Eight Roads Ventures, F-Prime Capital, Sequoia Capital, 6 Dimensions Capital, Fidelity
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai
#3
Series B · Suzhou, Jiangsu · founded 2021$22.1Mraised▾
Series B · Suzhou, Jiangsu · founded 2021
Developer of RNA-based drugs for multiple diseases. The company focuses on the development of innovative drugs and vaccines with RNA as the core for infectious diseases, tumor immunology, and metabolic diseases.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Funding
top 34%Moat
top 38%Talent
bottom 49%Market
bottom 37%Global
bottom 36%Funding: Raised $22.1M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) · Last round Series B (Oct 2025)
Moat: Editorial + unicorn rating 4/10 · Soonicorn
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 417 LinkedIn followers
Funding rounds
- Oct 2025Series B$44M
- May 2022Series A$22.1M
- Dec 2021Angel—
Founders & team
Investors
LYFE Capital, Source Code Capital, Hony Capital, Hillhouse, Sherpa Healthcare Partners, Hua Chuang Capital
#4
Seed · Suzhou, Jiangsu · founded 2020$10Mraised▾
Seed · Suzhou, Jiangsu · founded 2020
Provider of a platform utilizing Generative AI to accelerate drug discovery and development for the biotech and pharmaceutical industries. It utilises the power of Large Language Models specifically trained on biological languages to discover and develop effective drugs.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 41%AI
top 45%Talent
bottom 45%Global
bottom 33%Funding: Raised $10.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Dec 2025)
AI: Product described with: generative ai
Talent: 1 named leader on record
Funding rounds
- Dec 2025Seed$10M
Founders & team
Investors
Qiming Venture Partners
#5
Public · Nanjing, Jiangsu · founded 2009 · 7 employees$145.2Mraised▾
Public · Nanjing, Jiangsu · founded 2009 · 7 employees
Developer of small molecule therapeutics for the treatment of cancer. The company's product line include Senaparib is a PARP inhibitor for ovarian cancer maintenance therapy and small cell lung cancer, meeting primary endpoints in the FLAMES study for superior efficacy and safety. Other assets include WEE1 inhibitor IMP7068, ATR inhibitor IMP9064, and PARP1-selective inhibitor IMP1734 (collaborating with Eikon Therapeutics), alongside additional DDR inhibitors.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Patents
top 18%Funding
top 21%Innovation
top 23%Moat
top 26%Global
bottom 43%Market
bottom 26%Patents: 226 patents matched (strict assignee match) · 118 filings since 2022 vs 76 in 2017-21 · Latest publication 2026
Funding: Raised $145M across 5 rounds · 5 rounds over 12 yrs (0.4/yr) · Last round Series D (Nov 2024)
Innovation: 226 patents (top 11% of patent-holders) · 118 filings since 2022 vs 76 in 2017-21
Funding rounds
- Nov 2024Series D$34.5M
- Apr 2024Series D$55.2M
- Mar 2022Series D—
- Nov 2020Series C$50M
Investors
Lilly Asia Ventures, Cenova, 6 Dimensions Capital, ShenZhen GTJA Investment Group, Xicheng Jinrui, Yangzhou Guojin Investment Group
#6
Series C · Wuxi, Jiangsu · founded 2013 · 100 employees$15.5Mraised▾
Series C · Wuxi, Jiangsu · founded 2013 · 100 employees
Developer of a medical device for the treatment of pulmonary hypertension. The device PADN multipolar synchronous pulmonary artery radiofrequency ablation catheter transmits the high-frequency current for ablation of the pulmonary sympathetic nerve.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Moat
top 25%Patents
top 31%Innovation
top 33%Funding
top 38%Market
top 39%Growth
top 48%Moat: Editorial + unicorn rating 7/10 · IP moat: 38 patents
Patents: 38 patents matched (strict assignee match) · 27 filings since 2022 vs 10 in 2017-21 · Latest publication 2026
Innovation: 38 patents (top 54% of patent-holders) · 27 filings since 2022 vs 10 in 2017-21 · Deep-tech classification: Tech Hardware
Audience (LinkedIn): 2k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. global experts) announced in 12 mo
Funding rounds
- Mar 2025Series C$100M
- Nov 2022Series A—
- Aug 2021Series A$15.5M
Founders & team
Investors
Yuanbio Venture Capital, Orbimed, Cenova, Gaorong Capital, GC&H Investments, Huihe Capital
#7
Series C · Wuxi, Jiangsu · founded 2008$1.4Mraised▾
Series C · Wuxi, Jiangsu · founded 2008
Developer of disease diagnostic reagents. The company focuses on the development and labeling services of radioisotope-labeled compounds such as C14 and detection reagents for disease detection by tandem mass spectrometry.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Innovation
top 32%Moat
top 32%Patents
top 33%Talent
bottom 45%Funding
bottom 43%Global
bottom 29%Innovation: 49 patents (top 48% of patent-holders) · 42 filings since 2022 vs 7 in 2017-21
Moat: Editorial + unicorn rating 4/10 · IP moat: 49 patents
Patents: 49 patents matched (strict assignee match) · 42 filings since 2022 vs 7 in 2017-21 · Latest publication 2025
Funding rounds
- Oct 2025Series C$14M
- Oct 2022Seed$1.4M
Founders & team
Investors
jiangyinnewguoliangroup
#8
Seed · Nanjing, Jiangsu · founded 2021$13.6Mraised▾
Seed · Nanjing, Jiangsu · founded 2021
Developer of novel analgesic drugs targeting Nav1.8 and Nav1.7 ion channels. This company focuses on the research and development of innovative pain treatment medications. The company's research centers on two sodium ion channels, Nav1.8 and Nav1.7, which are closely linked to the body's pain perception. A team with extensive experience in innovative drug development leads the research efforts. The goal is to create new and effective pain relief therapies.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 42%Talent
top 45%Global
bottom 48%Funding: Raised $13.6M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Jan 2025)
Talent: 2 named leaders on record
Global: Investors from 1 country beyond China
Funding rounds
- Jan 2025Seed$13.6M
Founders & team
Investors
Qiming Venture Partners, THG Ventures, Insight Capital
#9
Series C · Suzhou, Jiangsu · founded 2019$1.1Braised▾
Series C · Suzhou, Jiangsu · founded 2019
Developer of mRNA-based therapeutics for cancer and infectious diseases. The company has developed proprietary technology platforms in mRNA design, in vitro synthesis, and LNP-based delivery systems to develop targeted therapies for infectious and immuno-oncology indications.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Moat
top 14%Patents
top 17%Innovation
top 22%Funding
top 27%Talent
top 38%Market
bottom 44%Moat: Editorial + unicorn rating 9/10 · IP moat: 157 patents · Unicorn
Patents: 157 patents matched (strict assignee match) · 154 filings since 2022 vs 3 in 2017-21 · Latest publication 2026
Innovation: 157 patents (top 17% of patent-holders) · 154 filings since 2022 vs 3 in 2017-21
Funding rounds
- May 2022Series C—
- Nov 2021Series C$300M
- Aug 2021Series C$720M
- Apr 2021Series B$91.6M
Founders & team
Investors
SoftBank Vision Fund, 5Y Capital, Chimera, Mirae Asset, Fortune Ocean, Oriental Fortune Capital
#10
Public · Suzhou, Jiangsu · founded 2011 · 5144 employees$535Mraised▾
Public · Suzhou, Jiangsu · founded 2011 · 5144 employees
Developer of antibody therapeutics for multiple diseases. It offers monoclonal and bispecific antibodies to treat several cancers such as non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, colorectal cancer, and lung cancer. Also, has antibody binding to TNF-α preventing it from activating TNF receptors, and will be used to treat Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn’s disease, and other autoimmune diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 35k LinkedIn followers — 14.1% of this cohort's audience
Activity: 1 partnerships (incl. Lilly) announced in 12 mo
Funding rounds
- Aug 2022Post IPO$307.9M
- Oct 2019Post IPO$299.8M
- Apr 2018Series E$150M
- Nov 2016Series D$260M
Founders & team
Investors
Sanofi, F-Prime Capital, Frontline BioVentures, Legend Capital, Lilly Asia Ventures, Temasek
Tech stack
Animate.CssBabelBaidu Analytics (百度统计)Core-JsNginxNode.Js
#11
Series D · Zhenjiang, Jiangsu · founded 2012$152Mraised▾
Series D · Zhenjiang, Jiangsu · founded 2012
Jiangsu develops drugs for various cancer and metabolic diseases. The company has various pipelined products like URAT-1 for gout and hyperuricemia disease and multiple targets drugs (ABP-6061 and ABP-431) for NASH, gastric cancer, colon cancer, and breast cancer.
Funding rounds
- Oct 2023Series D$83M
- Jan 2022Series C$47.2M
- Jan 2020Series B$21.9M
- Jun 2018Series A—
Founders & team
Investors
Optimal Capital Management, Zhongyu Capital, Kaitai Capital Management, Livzon Pharmaceutical, ShenZhen GTJA Investment Group, Yuanhe Holdings
#12
Series E · Suzhou, Jiangsu · founded 2017$97.3Mraised▾
Series E · Suzhou, Jiangsu · founded 2017
Developer of therapeutics for multiple diseases. It offers a drug pipeline that includes BLI inhibitors, EZH2 inhibitors, hURAT1 inhibitors, and antibody-drug conjugates for the treatment of cancer, infectious disease, and metabolic disease.
Funding rounds
- Feb 2024Series E$97.3M
Founders & team
Investors
Tencent, Tsinghua Holdings Capital, Jinan Industrial Development Investment Group, Chenhai Capital, Pudong Venture Capital, Yuekai Securities
Funding & investor landscape
$6Btotal disclosed funding
63companies funded
122disclosed rounds
1rounds last 90 days
Most active investors
Qiming Venture Partners11 rounds
Notable founders
Xiaohu Zhang
Co-Founder & CEO · Accropeutics
Sudan He
Co-Founder · Accropeutics
Peter Luo
Founder & CEO · Adagene
Rongkuan Hu
Founder · Starna Therapeutics
Jinquan Sun
Co-Founder & CEO · Convergen Pharmaceuticals
Jessie Lian
CEO · Pulnovo Medical
Zhu Chenggu
CEO · Beta Pharmaceutical Technology
Yang Yong
Co-Founder · Iongen Therepeutics
Lei Xiaoguang
Co-Founder · Iongen Therepeutics
Dr InBev
Co-Founder & Co-CEO · Abogen Biosciences
Ying Bo
Co-Founder & Co-CEO · Abogen Biosciences
Michael Yu
Founder & CEO · Innovent Bio
Prism market signals · China · country-scoped Prism corpus, 217,045 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN JIANGSU · Health & Bio
How research on Biotechnology in Jiangsu is moving
A read on the academic research around Biotechnology in Jiangsu — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 150 papers.
Jiangsu University and allied institutions lead Jiangsu's biotechnology research, focusing on cancer molecular mechanisms and plant-microbe interactions, with a cautiously optimistic tone amid mixed breakthrough and concern findings.
150 papers · stance +0.50 · 30% breakthrough · 15% concern
top institutions
- Jiangsu University60
- Jiangsu Academy of Agricultural Sciences33
- Jiangsu University of Science and Technology12
- Jiangsu Province Hospital11
- Jiangsu Cancer Hospital8
leading researchers
Hongyan Wang · Lei Wang · Xinjuan Hu · Yujie Lu · Abdul Salam · Ali Raza Khan
prism intelligence · tone & topics
93% positive · 5% critical tone
HealthAgriculturePharmaceuticalsMedical ResearchBiologyClinical Trials
▲
Breakthroughs41 · 27%
▲ 0%→26% share
0 median citations85% since 2021mostly methods-led
Virus and cancer research are newly emerging breakthrough topics, each surging to 4 and 3 papers as Jiangsu biotech breakthroughs grew from 0%→26% field-share.
rising sub-themes (early→recent)
- Virus4
- Cancer research3
- Downregulation and upregulation3
- Viral replication3
- Gene3
Newly emergingVirus 0→4 · Downregulation and upregulation 0→3 · Gene 0→3
Landmark METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner · 739 cites
◆
Advancements76 · 51%
▼ 100%→49% share
▼0.5× share momentum0 median citations87% since 2021mostly empirical
Antioxidant research newly emerged with 6 papers as advancements shifted, while oxidative stress and gene knockdown each tripled to 3 papers.
rising sub-themes (early→recent)
- Oxidative stress1→3
- Gene knockdown1→3
- Gene1→3
Newly emergingAntioxidant 0→6 · Transcriptome 0→5 · Downregulation and upregulation 0→4
Landmark METTL3-mediated m 6 A modification of HDGF mRNA promotes gastric cancer progression and has prognostic signif · 942 cites
▼
Concerns20 · 13%
▲ 0%→15% share
0 median citations100% since 2021mostly reviews
Agriculture, mycotoxin, and sustainable agriculture concerns are brand-new, collectively driving Jiangsu biotech's concern segment from 0%→15% field-share.
rising sub-themes (early→recent)
- Agriculture5
- Mycotoxin3
- Sustainable agriculture3
- Population2
- Human health2
Newly emergingAgriculture 0→5 · Mycotoxin 0→3 · Sustainable agriculture 0→3
Landmark A comprehensive review of ultrasonic assisted extraction (UAE) for bioactive components: Principles, advantages, equipme · 641 cites
Common questions
How many Life Sciences companies are there in Jiangsu, China?
Radar tracks 191 indexable Life Sciences companies headquartered in Jiangsu, China that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Jiangsu, China?
The Life Sciences companies in Jiangsu, China on this list have raised a combined $6B in disclosed equity funding across 63 funded companies.
Which is the highest-funded Life Sciences company in Jiangsu, China?
Abogen Biosciences is the highest-funded Life Sciences company in Jiangsu, China, with $1.1B in disclosed equity funding.
How many Life Sciences companies in Jiangsu, China are funded?
63 of the 191 Life Sciences companies in Jiangsu, China on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Jiangsu, China?
2 Life Sciences companies in Jiangsu, China on this list are valued at $1B or more.
Who are the top investors in Jiangsu, China Life Sciences companies?
The most active investors in Jiangsu, China Life Sciences companies on this list include Lilly Asia Ventures, Yuanbio Venture Capital, Qiming Venture Partners, Hillhouse, Loayal Valley Capital.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.